Fresenius Kabi is currently trading at Rs. 128.00, up by 17.60 points or 15.94% from its previous closing of Rs. 110.40 on the BSE.
The scrip opened at Rs. 132.45 and has touched a high and low of Rs. 132.45 and Rs. 126.00 respectively. So far 556099 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 152.45 on 17-Apr-2013 and a 52 week low of Rs. 78.50 on 18-Oct-2012.
Last one week high and low of the scrip stood at Rs. 114.60 and Rs. 105.20 respectively. The current market cap of the company is Rs. 2041.14 crore.
The promoters holding in the company stood at 81.00% while Institutions and Non-Institutions held 9.91% and 9.09% respectively.
Fresenius Kabi Oncology has received approval from Securities and Exchange Board of India (SEBI) to delist its shares from the Indian stock market. As per the SEBI’s order, the healthcare firm has to complete the delisting process within three months. The market regulator also said that the company would have to take into account its pre-OFS (Offer for Sale) promoter holding of October 2012 to determine the minimum number of shares to be acquired for the delisting.
As on September 2012, Fresenius Kabi (Singapore) Pte, the parent firm held 90% stake in the company, while remaining 10% stake were with the public shareholders.
Fresenius Kabi Oncology manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |